Seranova Bio is discovering the functional antibody responses that shape health and disease.

Clinical trials occur when a fraction of patients develop autoantibodies to a specific target. If patients with a specific autoantibody reactivity benefit from lessened disease severity or better outcomes, a therapeutic antibody with the same reactivity may benefit other patients. Seranova Bio’s proprietary technology generates the most accurate and extensive collection of these “studies” ever assembled, effectively giving Seranova and its collaborators exclusive access to the results. Targets validated by these “natural trials” will fuel Seranova’s pipeline of first-in-class therapeutics.